UMIN ID: UMIN000055606
Registered date:24/09/2024
Survey research of patient and physician communication in the treatment of newly diagnosed transplant ineligible multiple myeloma
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | newly diagnosed transplant ineligible multiple myeloma |
| Date of first enrollment | 2024/09/24 |
| Target sample size | 200 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | To investigate the current state of patient-physician communication in the treatment of NDMM both at the start of treatment and after disease control. |
|---|---|
| Secondary Outcome | To identify changes in patients' knowledge, mental status, values, treatment goals, and preferences regarding treatment decisions at the start of treatment and after disease control. |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | (Patients) 1.Patients who cannot complete responses to the questionnaire (Doctors) No settings |
Related Information
| Primary Sponsor | Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Yuta Okamura |
| Address | 2-1 -1 Nihonbashi Honcho, Chuo-ku, Tokyo JAPAN Japan 103-8668 |
| Telephone | 03-3278-2111 |
| japan.oncology.iir.office@takeda.com | |
| Affiliation | Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit |
| scientific contact | |
| Name | Junpei Soeda |
| Address | 2-1 -1 Nihonbashi Honcho, Chuo-ku, Tokyo JAPAN Japan |
| Telephone | 03-3278-2111 |
| japan.oncology.iir.office@takeda.com | |
| Affiliation | Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit |